1 5479 136 RESVERATROL ATTENUATES CIGARETTE SMOKE EXTRACT INDUCED CELLULAR SENESCENCE IN HUMAN AIRWAY EPITHELIAL CELLS BY REGULATING THE MIR-34A/SIRT1/NF-KAPPAB PATHWAY. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS CHARACTERIZED BY ACCELERATED LUNG AGING. SMOKING IS THE CRITICAL RISK FACTOR FOR COPD. CELLULAR SENESCENCE OF AIRWAY EPITHELIAL CELLS IS THE CYTOLOGICAL BASIS OF ACCELERATED LUNG AGING IN COPD, AND THE REGULATION OF MICRORNAS (MIRNAS) IS THE CENTRAL EPIGENETIC MECHANISM OF CELLULAR SENESCENCE. RESVERATROL (RES) IS A POLYPHENOL WITH ANTI-AGING PROPERTIES. THIS STUDY INVESTIGATED WHETHER RES ATTENUATES CIGARETTE SMOKE EXTRACT (CSE)-INDUCED CELLULAR SENESCENCE IN HUMAN AIRWAY EPITHELIAL CELLS (BEAS-2B) THROUGH THE MIR-34A/SIRT1/NUCLEAR FACTOR-KAPPAB (NF-KAPPAB) PATHWAY. BEAS-2B CELLS WERE TREATED WITH RES, CSE AND TRANSFECTED WITH MIR-34A-5P MIMICS. CELLULAR SENESCENCE WAS EVALUATED BY SENESCENCE -RELATED BETA-GALACTOSIDASE (SA-BETA-GAL) STAINING AND EXPRESSION OF SENESCENCE-RELATED GENES (P16, P21, AND P53). THE EXPRESSIONS OF MIR-34A-5P, SIRT1, AND NF-KAPPAB P65 WERE EXAMINED USING QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION AND WESTERN BLOTTING. THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) CYTOKINES (IL-1BETA, IL-6, IL-8, TNF-ALPHA) WERE ASSESSED BY ENZYME-LINKED IMMUNOSORBENT ASSAY. THE BINDING BETWEEN MIR-34A-5P AND SIRT1 WAS CONFIRMED BY DUAL-LUCIFERASE REPORTER ASSAY. THE RESULTS SHOWED THAT CSE DOSE-DEPENDENTLY DECREASED CELL VIABILITY AND ELEVATED CELLULAR SENESCENCE, CHARACTERIZED BY INCREASED SA-BETA-GAL STAINING AND SENESCENCE-RELATED GENE EXPRESSIONS (P16, P21, AND P53). FURTHER, CSE DOSE-DEPENDENTLY INCREASED THE EXPRESSION OF MIR-34A-5P AND SASP CYTOKINES (IL-1BETA, IL-6, IL-8, TNF-ALPHA) IN BEAS-2B CELLS. PRETREATMENT WITH RES INHIBITED CSE-INDUCED CELLULAR SENESCENCE AND SECRETION OF SASP CYTOKINES (IL-1BETA, IL-6, IL-8, TNF-ALPHA) IN A DOSE-DEPENDENT MANNER. MOREOVER, RES REVERSED THE CSE-INDUCED DOWN-REGULATION OF SIRT1 AND UP-REGULATION OF MIR-34A-5P AND NF-KAPPAB P65. SIRT1 IS A TARGET OF MIR-34A-5P. OVEREXPRESSION OF MIR-34A-5P VIA TRANSFECTION WITH MIR-34A-5P MIMIC IN BEAS-2B CELLS ATTENUATED THE INHIBITORY EFFECT OF RES ON CELLULAR SENESCENCE, ACCOMPANIED BY REVERSING THE EXPRESSION OF SIRT1 AND NF-KAPPAB P65. IN CONCLUSION, RES ATTENUATED CSE-INDUCED CELLULAR SENESCENCE IN BEAS-2B CELLS BY REGULATING THE MIR-34A/SIRT1/NF-KAPPAB PATHWAY, WHICH MAY PROVIDE A NEW APPROACH FOR COPD TREATMENT. 2022 2 5227 38 PRMT6 MEDIATES INFLAMMATION VIA ACTIVATION OF THE NF-KAPPAB/P65 PATHWAY ON A CIGARETTE SMOKE EXTRACT-INDUCED MURINE EMPHYSEMA MODEL. INTRODUCTION: SMOKE-DRIVEN LUNG INFLAMMATION IS CONSIDERED TO BE THE MAJOR PATHOPHYSIOLOGY MECHANISM OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)/EMPHYSEMA. PROTEIN ARGININE METHYLTRANSFERASE 6 (PRMT6) IS A KEY EPIGENETIC ENZYME, WHICH IS RELATED TO PROTECTING THE TRI-METHYLATION OF H3K4 (H3K4ME3). WE HYPOTHESIZED THAT PTMT6 PROTECTS LUNG INFLAMMATION THROUGH THE NUCLEAR FACTOR KAPPA B (NF-KAPPAB) PATHWAY. METHODS: MICE WERE INJECTED WITH CIGARETTE SMOKE EXTRACT (CSE) OR PBS TO ESTABLISH A MICE MODEL, INTRATRACHEALLY INSTILLED WITH OVEREXPRESSED PRMT6 OR NEGATIVE CONTROL VECTOR. MORPHOMETRY OF LUNG SLIDES AND LUNG FUNCTION WERE MEASURED. WE DETERMINED THE PROTEIN EXPRESSION OF PRMT6 AND ITS RELATED HISTONE TARGETS, THE ACTIVATION OF NF-KAPPAB PATHWAY, THE LEVEL OF TUMOR NECROSIS FACTOR ALPHA (TNFALPHA) AND INTERLEUKIN-1BETA (IL-1BETA). RESULTS: AFTER PRMT6 OVEREXPRESSION, THE MORPHOMETRY INDEXES AND LUNG FUNCTION WERE IMPROVED. ALSO, THE EXPRESSION OF H3K4ME3 WAS DECREASED. OVEREXPRESSED PRMT6 COULD SUPPRESS CSE-INDUCED NF-KAPPAB ACTIVATION AND PRO-INFLAMMATION GENES EXPRESSION. CONCLUSIONS: THE OVEREXPRESSED PRMT6 COULD SERVE AS AN INFLAMMATION INHIBITOR, POTENTIALLY THROUGH BLOCKING THE NF-KAPPAB/P65 PATHWAY IN THE MURINE EMPHYSEMA MODEL. 2020 3 3983 43 LONG-TERM EXPOSURE TO CIGARETTE SMOKE EXTRACT INDUCES HYPOMETHYLATION AT THE RUNX3 AND IGF2-H19 LOCI IN IMMORTALIZED HUMAN UROTHELIAL CELLS. CIGARETTE SMOKING IS THE SINGLE MOST IMPORTANT EPIDEMIOLOGICAL RISK FACTOR FOR BLADDER CANCER BUT IT IS NOT KNOWN WHETHER EXPOSURE OF UROTHELIAL CELLS TO THE SYSTEMIC SOLUBLE CONTENTS OF CIGARETTE SMOKE IS DIRECTLY CAUSATIVE TO BLADDER CANCER AND THE ASSOCIATED EPIGENETIC CHANGES SUCH AS TUMOR SUPPRESSOR GENE HYPERMETHYLATION. WE UNDERTOOK THIS STUDY TO INVESTIGATE IF LONG-TERM TREATMENT OF HUMAN UROTHELIAL CELLS WITH CIGARETTE SMOKE EXTRACT (CSE) RESULTS IN TUMOR SUPPRESSOR GENE HYPERMETHYLATION, A PHENOTYPE THAT WAS PREVIOUSLY ASSOCIATED WITH LONG-TERM CONSTANT CSE TREATMENT OF AIRWAY EPITHELIAL CELLS. WE CHRONICALLY TREATED AN IMMORTALIZED HUMAN UROTHELIAL CELL LINE UROTSA WITH CSE USING A CYCLIC DAILY REGIMEN BUT THE CELLS WERE CULTURED IN CSE-FREE MEDIUM BETWEEN DAILY TREATMENTS. BISULFITE SEQUENCING AND REAL-TIME PCR ARRAY-BASED METHYLATION PROFILING WERE EMPLOYED TO EVALUATE METHYLATION CHANGES AT TUMOR SUPPRESSOR GENE LOCI IN THE CHRONICALLY CSE-TREATED CELLS VERSUS THE PASSAGE-MATCHED UNTREATED CONTROL CELLS. THE RUNX3 TUMOR SUPPRESSOR GENE PROMOTER WAS HYPOMETHYLATED WITH A SIGNIFICANT INCREASE IN PROPORTION OF THE COMPLETELY UNMETHYLATED HAPLOTYPE AFTER THE LONG-TERM CSE TREATMENT; WHEREAS RUNX3 PROMOTER HYPERMETHYLATION WAS PREVIOUSLY REPORTED FOR BLADDER CANCERS OF SMOKERS. HYPOMETHYLATION INDUCED BY THE LONG-TERM CSE TREATMENT WAS ALSO OBSERVED FOR THE IGF2-H19 LOCUS. THE METHYLATION STATUS AT THE PRSS8/PROSTASIN AND 16 ADDITIONAL LOCI HOWEVER, WAS UNAFFECTED BY THE CHRONIC CSE TREATMENT. TRANSIENT CSE TREATMENT OVER 1 DAILY REGIMEN RESULTED IN TRANSCRIPTIONAL DOWN-REGULATION OF RUNX3 AND H19, BUT ONLY THE H19 TRANSCRIPTION WAS DOWN-REGULATED IN THE CHRONICALLY CSE-TREATED UROTHELIAL CELLS. TRANSCRIPTION OF A KEY ENZYME IN ONE-CARBON METABOLISM, DIHYDROFOLATE REDUCTASE (DHFR) WAS GREATLY REDUCED BY THE LONG-TERM CSE TREATMENT, POTENTIALLY SERVING AS A MECHANISM FOR THE HYPOMETHYLATION PHENOTYPE VIA A REDUCED SUPPLY OF METHYL DONOR. IN CONCLUSION, CHRONIC CYCLIC CSE TREATMENT OF UROTHELIAL CELLS INDUCED HYPOMETHYLATION RATHER THAN HYPERMETHYLATION AT SPECIFIC LOCI. 2013 4 3449 48 HYPERMETHYLATION OF THE NRF2 PROMOTER INDUCES FERROPTOSIS BY INHIBITING THE NRF2-GPX4 AXIS IN COPD. BACKGROUND: NUCLEAR FACTOR E2-RELATED FACTOR 2 (NRF2) IS INVOLVED IN OXIDATIVE STRESS AND LUNG INFLAMMATION AND REGULATES THE ETIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). FERROPTOSIS IS CHARACTERIZED BY THE ACCUMULATION OF LIPID REACTIVE OXYGEN SPECIES (ROS) VIA FERROUS ION-DEPENDENT FENTON REACTIONS AND IS INVOLVED IN COPD. HOWEVER, THE ROLE OF NRF2 IN FERROPTOSIS AND ITS EPIGENETIC REGULATION IN THE PATHOGENESIS OF COPD REMAIN UNCLEAR. METHODS: FERROPTOSIS WAS DETECTED BY 4-HNE, MDA, C11BODIPY, DCFH-DA, PEALS' STAINING AND CCK-8 ASSAYS. QPCR AND WESTERN BLOTTING WERE PERFORMED TO EXAMINE THE NRF2 LEVELS IN PERIPHERAL LUNG TISSUES, PRIMARY EPITHELIAL CELLS COLLECTED FROM PATIENTS WITH COPD AND SUBJECTS WITH NORMAL PULMONARY FUNCTION (NEVER-SMOKER [CONTROL-NS]; SMOKER [CONTROL-S]), AND CIGARETTE SMOKE EXTRACT (CSE)-TREATED HUMAN BRONCHIAL EPITHELIAL (HBE) CELLS. ELISA WAS USED TO QUANTIFY IL-8 AND IL-1BETA LEVELS. METHYLATION OF THE NRF2 PROMOTER WAS ANALYZED BY BISULFITE SEQUENCING AND PYROSEQUENCING. RESULTS: FERROPTOSIS WAS INVOLVED IN COPD AND GLUTATHIONE PEROXIDASE 4 (GPX4) EXPRESSION WAS DOWNREGULATED IN THE COPD GROUP. REACTIVE OXYGEN SPECIES (ROS), LIPID PEROXIDES AND MDA WERE INCREASED, BUT GPX4 AND SOD WERE EXHAUSTED IN CSE-TREATED HBE CELLS. THE PRODUCTION OF IL-1BETA AND IL-8 WAS PROMOTED IN HBE CELLS IN RESPONSE TO CSE BUT COULD BE REVERSED BY THE FERROPTOSIS INHIBITOR FER-1. THE NRF2 LEVEL WAS SIGNIFICANTLY DECREASED IN THE COPD GROUP COMPARED WITH THE CONTROL-S AND CONTROL-NS GROUPS. INCREASED NRF2 EXPRESSION ENHANCED GPX4 AND SOD LEVELS AND INHIBITED FERROPTOSIS AND PROINFLAMMATORY CYTOKINES IN THE SUPERNATANT. INHIBITION OF GPX4 REVERSED THE EFFECT OF NRF2 OVEREXPRESSION AND PROMOTED FERROPTOSIS. TWO SPECIFIC CPG SITES WITHIN THE NRF2 PROMOTER WERE HYPERMETHYLATED IN THE COPD GROUP. SIMILARLY, CSE-TREATED HBE CELLS EXHIBITED HYPERMETHYLATION OF THE NRF2 GENE. CONCLUSION: NRF2 EXPRESSION WAS DOWNREGULATED IN THE LUNGS OF COPD PATIENTS DUE TO HYPERMETHYLATION OF THE NRF2 PROMOTER, INHIBITING NRF2/GPX4 AND FERROPTOSIS, WHICH IS RELATED TO THE INITIATION AND PROGRESSION OF COPD. TARGETING NRF2/GPX4 MAY INHIBIT FERROPTOSIS, WHICH COULD PROVIDE STRATEGIES TO DELAY OR TREAT COPD. 2021 5 3447 41 HYPERMETHYLATION OF MITOCHONDRIAL TRANSCRIPTION FACTOR A INDUCED BY CIGARETTE SMOKE IS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. PURPOSE OF THE STUDY: CIGARETTE SMOKING IS A LEADING ENVIRONMENTAL CONTRIBUTOR TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BUT ITS EPIGENETIC REGULATION OF MTTFA GENE REMAINS ELUSIVE. THIS STUDY AIMS TO EXPLORE THE RELATIONSHIP OF DNA METHYLATION OF MTTFA AND CIGARETTE SMOKING IN COPD. MATERIALS AND METHODS: WE ANALYZED DNA METHYLATION ON MTTFA PROMOTERS IN CLINICAL SAMPLES FROM COPD PATIENTS AND SUBJECTS WITH NORMAL PULMONARY FUNCTION. EXPRESSION OF MTTFA MRNA IN THE CLINICAL SAMPLES AND MTTFA MRNA AND PROTEIN IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS(HUVECS) TREATED WITH CIGARETTE SMOKE EXTRACT (CSE) WAS EVALUATED. MTTFA MRNA AND PROTEIN LEVELS WERE MEASURED TO DETERMINE EFFECTS OF DEMETHYLATION AGENTS ON CSE-TREATED HUVECS. RESULTS: THE DNA METHYLATION LEVEL OF THE MTTFA PROMOTER WAS SIGNIFICANTLY INCREASED IN COPD GROUP. EXPRESSION OF MTTFA MRNA WAS DOWNREGULATED IN THE LUNGS AS A CONSEQUENCE OF HYPERMETHYLATION OF MTTFA PROMOTER. EXPRESSION OF MTTFA MRNA AND PROTEIN WAS DOWNREGULATED IN CSE-TREATED HUVECS AS A CONSEQUENCE OF HYPERMETHYLATION OF THE MTTFA PROMOTER. MTTFA EXPRESSION IN CSE-TREATED HUVECS WAS RESTORED BY THE METHYLATION INHIBITOR, 5-AZA-2'-DEOXYCYTIDINE(AZA). CONCLUSIONS: CIGARETTE SMOKE-INDUCED HYPERMETHYLATION OF THE MTTFA PROMOTER IS RELATED TO THE INITIATION AND PROGRESSION OF COPD. OUR FINDING MAY PROVIDE A NEW STRATEGY FOR THE INTERVENTION OF COPD BY DEVELOPING DEMETHYLATION AGENTS TARGETING MTTFA HYPERMETHYLATION. 2019 6 3828 35 INVOLVEMENT OF B-CELL CLL/LYMPHOMA 2 PROMOTER METHYLATION IN CIGARETTE SMOKE EXTRACT-INDUCED EMPHYSEMA. ABNORMAL APOPTOTIC EVENTS PLAY AN IMPORTANT ROLE IN THE PATHOGENESIS OF EMPHYSEMA. THE B-CELL CLL/LYMPHOMA 2 (BCL-2) FAMILY PROTEINS ARE ESSENTIAL AND CRITICAL REGULATORS OF APOPTOSIS. WE DETERMINED WHETHER THE ANTI-APOPTOTIC BCL-2 PLAY A ROLE IN THE CIGARETTE SMOKE EXTRACT (CSE)-INDUCED EMPHYSEMA. FURTHERMORE, GIVEN THE INVOLVEMENT OF EPIGENETICS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE, WE HYPOTHESIZED THAT THE DEREGULATION OF BCL-2 MIGHT BE CAUSED BY GENE METHYLATION. THE EMPHYSEMA IN BALB/C MICE WAS ESTABLISHED BY INTRAPERITONEALLY INJECTION OF CSE. 5-AZA-2'-DEOXYCYTIDINE (AZA; A DEMETHYLATION REAGENT) AND PHOSPHATE-BUFFERED SALINE WERE ALSO ADMINISTERED INTRAPERITONEALLY AS CSE. TUNEL ASSAY WAS USED TO ASSESS APOPTOTIC INDEX OF PULMONARY CELLS. THE METHYLATION STATUS OF CPG DINUCLEOTIDES WITHIN THE BCL-2 PROMOTER WAS OBSERVED IN ALL GROUPS BY BISULFITE SEQUENCING PCR. PULMONARY EXPRESSION OF BCL-2, BAX, AND CYTOCHROME C WERE MEASURED AFTER FOUR WEEKS OF TREATMENT. THE APOPTOTIC INDEX OF PULMONARY CELLS IN CSE INJECTION GROUP WAS MUCH HIGHER THAN CONTROL ((25.88 +/- 7.55)% VS (6.28 +/- 2.96)%). COMPARED TO CONTROL MICE, DECREASED EXPRESSION OF BCL-2 AND HIGH METHYLATION OF BCL-2 PROMOTER WAS OBSERVED IN CSE INJECTED MICE (0.88 +/- 0.08 VS 0.49 +/- 0.11, (3.82 +/- 1.34)% VS (35.68 +/- 5.99)%, P < 0.01).CSE TREATMENT INDUCED LUNG CELL APOPTOSIS AND DECREASED LUNG FUNCTION. AZA TREATMENT INCREASED BCL-2 EXPRESSION WITH BCL-2 PROMOTER DEMETHYLATION. AZA ALSO ALLEVIATED THE LUNG CELL APOPTOSIS AND FUNCTION FAILURE CAUSED BY CSE TREATMENT. THE DECREASED EXPRESSION OF ANTI-APOPTOTIC BCL-2 MIGHT ACCOUNT FOR THE INCREASED APOPTOSIS IN CSE INDUCED-EMPHYSEMA. APPARENTLY, EPIGENETIC ALTERNATION PLAYED A ROLE IN THIS DEREGULATION OF BCL-2 EXPRESSION, AND IT MIGHT SUPPORT THE INVOLVEMENT OF EPIGENETIC EVENTS IN THE PATHOGENESIS OF EMPHYSEMA. 2016 7 3939 39 LNC-IL7R ALLEVIATES PM(2.5)-MEDIATED CELLULAR SENESCENCE AND APOPTOSIS THROUGH EZH2 RECRUITMENT IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. BACKGROUND: LONG-TERM EXPOSURE TO PM(2.5) (PARTICULATE MATTER WITH AN AERODYNAMIC DIAMETER OF